Arovella Therapeutics Ltd has released a press release.
Arovella licenses novel solid tumour targeting technology
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Reinstatement to Quotation
- Suspension from Quotation
- Response to ASX Price Query
- Quarterly Appendix 4C and Activities Report
- Completion of oversubscribed Share Purchase Plan (SPP)
Later from Arovella Therapeutics
- Arovella receives R&D tax credit of $1.94 million
- Arovella licenses novel CAR-iNKT cell armouring technology
- Appendix 4D and Half Year Report
- Pause in Trading
- Arovella Completes $12.5M Placement - Funded to Phase 1 Data
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics